Alexion Pharmaceuticals, Inc.

NASDAQ: ALXN
$182.50
+$0.00 (+0.0%)
Closing Price on July 28, 2021

ALXN Articles

After a wretched 2016, when many of the top biotech companies were hit hard by campaign rhetoric, the industry has roared back to life this year. Here are four big opportunities for aggressive...
The July 14 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The June 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Most of the large biotech outfits in America have gone into a limbo mode. Alexion Pharmaceuticals fits that bill despite its more than $26 billion market cap. Is it possible that some real good...
Wednesday saw a mixed reaction in the broad markets with the S&P 500 and Nasdaq largely down offsetting Tuesdays gains, and the Dow remaining relatively flat. Crude oil was perhaps the biggest...
Shares of Alexion Pharmaceuticals saw a handy gain early on Wednesday after the company announced that there would be changes in its leadership.
The May 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
These are four of the top pick stocks from Credit Suisse with 50% to 100% upside targets.
Avon, Noble Corp., Fitbit, and Alexion Pharma posted new 52-week lows Friday.
The May 15 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Thursday include Akamai Technologies, Alexion Pharmaceuticals, Altria, Chipotle Mexican Grill, MEI Pharma, Netflix and PayPal.
Chico's FAS, Southwestern Energy, Teva, and Alexion all posted new 52-week lows Wednesday.
Alexion, Teva, DSW, and Cerus all posted new 52-week lows on Tuesday.
The April 28 short interest data have been compared with the previous report, and moves in the selected biotech stocks were mixed.